<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748331</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-060</org_study_id>
    <nct_id>NCT01748331</nct_id>
  </id_info>
  <brief_title>The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia</brief_title>
  <acronym>Decongest</acronym>
  <official_title>The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finn Gustafsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of fluid restriction and the
      neurohormonal mechanisms in the development of hyponatremia in patients with congestive heart
      failure and hyponatremia. The hypothesis is that strict fluid restriction leads to a larger
      increase in plasma sodium than standard treatment in patients with decompensated heart
      failure associated with hyponatremia. A secondary hypothesis is that the neurohormonal change
      is greater in patients treated with strict fluid restriction versus standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma sodium from day 1 to day 4: - Normalization of plasma sodium or - A significant change in plasma sodium of a minimum of 5 mmol/L from baseline to day 4</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma vasopressin and copeptin</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure, heart rate, weight and oedemas</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnoea assessed by the patient</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until clinical stability</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between hospitalization time and plasma sodium</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between fluid restriction and change in kidney function</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of fluid restriction</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance to fluid restriction</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Strict fluid restriction &lt; 1 L/day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be randomized to strict fluid restriction &lt; 1 L/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate fluid restriction &lt; 2.5 L/day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients will be randomized to moderate fluid restriction &lt; 2.5 L/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid restriction</intervention_name>
    <description>Patients will be randomized to strict fluid restriction &lt; 1 L/day versus moderate fluid restriction &lt; 2.5 L/day</description>
    <arm_group_label>Strict fluid restriction &lt; 1 L/day</arm_group_label>
    <arm_group_label>Moderate fluid restriction &lt; 2.5 L/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Left Ventricular Ejection Fraction (LVEF) &lt; 40

        At least two of the following signs of decompensated heart failure and fluid retention:

          -  Weight gain &gt; 2 kg

          -  Pulmonal Congestion

          -  Jugular vein congestion

          -  Peripheral oedemas

          -  Hepatic congestion with ascites

          -  Radiographic signs of fluid retention

          -  Increased diuretic dose

        And

          -  New York Heart Association (NYHA) class III-IV

          -  Plasma sodium &lt; 135 mmol/L

          -  Symptomatic heart failure and treatment with relevant heart failure medications
             (beta-blocker, diuretic, digoxin, angiotensin-converting-enzyme inhibitor,
             angiotensin-II receptor antagonist, spironolactone, hydralazine and/or nitrates)for at
             least 1 month

          -  Hospitalization for decompensated heart failure within the last 48 hours

          -  Given informed consent

        Exclusion Criteria:

          -  Plasma sodium ≥ 135 mmol/L before randomization

          -  Reduced kidney function (creatinine &gt; 200 μmol/L)

          -  Severe hematologic disease

          -  Hypovolemic hyponatremia (volume depletion or dehydration)

          -  Intolerability to large or fast changes in fluid volume assessed by the investigator

          -  Plasma sodium &lt; 120 mmol/L accompanied by neurologic symptoms

          -  Anuria

          -  Symptomatic systolic blood pressure (supine systolic blood pressure &lt; 90 mmHg)

          -  Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg)

          -  Uncontrolled diabetes diabetes mellitus

          -  Adrenal insufficiency

          -  Acute myocardial infarction, sustained ventricular tachycardia or ventricular
             fibrillation within the last 30 days

          -  Heart surgery within the last 60 days

          -  Other severe heart disease: hypertrophic cardiomyopathy, severe heart valve disease,
             cardiac amyloidosis, active myocarditis, pericardial exudate which is hemodynamically
             significant

          -  Left ventricular assist device (LVAD)

          -  Planned revascularization procedure, electrophysiologic device implantation, mechanic
             left ventricular assist device, heart transplant or any other heart surgery procedures
             within the next 30 days

          -  Cerebrovascular event within the last 6 months

          -  Comorbidity with an expected survival &lt; 6 months

          -  Other reasons for hyponatremia: Primary syndrome of inappropriate antidiuretic hormone
             secretion (SIADH), primary polydipsia, head trauma, uncontrolled hypothyroidism,
             adrenal insufficiency or other known pharmacologically triggered hyponatremia which is
             reversible upon discontinuation of the drug, hyperglycemia (pseudohyponatremia),
             present abuse of alcohol

          -  Pregnancy

          -  Pregnant or fertile women who are not using safe contraception

          -  Dementia

          -  Unwilling or unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <phone>004535459743</phone>
    <email>finn.gustafsson@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Balling, MD</last_name>
    <phone>004523451679</phone>
    <email>louise.balling@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>1718</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
      <phone>004535459743</phone>
      <email>finn.gustafsson@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Louise Balling, MD</last_name>
      <phone>004523451679</phone>
      <email>louise.balling@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Balling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav Wendelboe Nielsen, MD, DMSc</last_name>
      <phone>004535316448</phone>
      <email>owen0002@bbh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Olav W Nielsen, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Staff Cardiologist, PhD, DMSci</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Hyponatremia</keyword>
  <keyword>Fluid restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

